On July 8, Duality Biotherapeutics-B rose 5.33% in regular trading, trading at HK$222.0/share, with turnover of approximately HK$74.52 million.

On the news front, Soochow Securities initiated coverage on the company with a Buy rating and a target price of HK$418.61, implying nearly 90% upside from the current share price. The initiation comes amid multiple positive catalysts, including the company's STAR Market IPO review status recently advancing to the inquiry stage, its previously announced share buyback plan of up to US$40 million, and the completion of first patient dosing in the global Phase III pivotal registration trial for DB-1311/BNT324, a B7-H3-targeting ADC co-developed with BioNTech for the treatment of metastatic castration-resistant prostate cancer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)